EKF Diagnostics Investor Announcements


EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.

Strong double-digit growth in underlying (non-COVID) revenue

TR-1: Standard form for notification of major holdings

Purchase of shares in EKF Diagnostics Holdings plc.

Approval of dividend in specie of investment in Verici Dx plc

EKF Diagnostics provides an update following the strengthening of its cash position.

9th Jun 2022

Enabling hospitals, labs and GPs to manage and evaluate patient data easily and securely

EKF announces the completion of the Company’s buyback programme

EKF announces that at the Annual General Meeting held earlier today, all resolutions were duly passed.

18th May 2022

EKF provides an update to shareholders ahead of its Annual General Meeting

EKF announces that the Board of EKF has been informed that on Thursday 28 April 2022, certain funds connected to Christopher Mills, Non-executive Chairman.